Reinventing the discovery, development, and commercialization of new medicines

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Read the full press release here

- IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab
- No decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohort
- IMVT-1402 is being developed as a simple SC injection

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in IgG in initial data from a Phase 1 clinical trial in healthy adults, with no dose-related changes in serum albumin or LDL-C, bolstering IMVT-1402 as a potential best-in-class neonatal fragment crystallizable receptor (FcRn) inhibitor.

Roivant named to Fast Company's Best Workplaces for Innovators List

See the full list here

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

Read the full press release here

Collecting Pharma’s Scraps Can Pay Off for This Biotech

Wall Street Journal

One person’s trash can be another’s treasure. That is essentially the idea behind Roivant ROIV -4.92%decrease; red down pointing triangle, a biotech company with a handful of drugs it got from pharma’s dustbin.

Roivant was founded on the premise that large biotech and pharma companies are often too big and complex, creating an opportunity for companies that can focus on a single therapy. The company, which creates a subsidiary “vant” for each new drug it gets, has had both failures and successes, including a notable late-stage flop in Alzheimer’s as well as the $3 billion sale of five of its companies to Japan’s Sumitomo Pharma.